Point72 DIFC Ltd Makes New Investment in Perspective Therapeutics, Inc. (NYSE:CATX)

Point72 DIFC Ltd bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,842 shares of the company’s stock, valued at approximately $118,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Sykon Capital LLC raised its position in shares of Perspective Therapeutics by 4.7% in the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after buying an additional 1,717 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics in the 2nd quarter valued at about $117,000. The Manufacturers Life Insurance Company purchased a new position in Perspective Therapeutics in the 2nd quarter worth approximately $188,000. ZWJ Investment Counsel Inc. acquired a new position in shares of Perspective Therapeutics during the 1st quarter worth approximately $26,000. Finally, Renaissance Technologies LLC grew its position in shares of Perspective Therapeutics by 94.2% in the second quarter. Renaissance Technologies LLC now owns 61,660 shares of the company’s stock valued at $615,000 after purchasing an additional 29,914 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 5.7 %

CATX stock opened at $12.59 on Wednesday. The company has a fifty day moving average price of $13.81. Perspective Therapeutics, Inc. has a 12-month low of $2.20 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. On average, research analysts expect that Perspective Therapeutics, Inc. will post -0.86 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on CATX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Wedbush started coverage on shares of Perspective Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $25.00 target price on the stock. Oppenheimer dropped their price target on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Bank of America began coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Finally, Truist Financial assumed coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average price target of $20.71.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.